Skip to navigation Skip to content

External Grants

2019

University of Missouri-Columbia (MU)

Midwest Biomedical Accelerator Consortium (MBArC)

Funding:
NIH National Heart, Lung and Blood Institute, $3,937,578 (anticipated)
Description:
To impact society, science must be translated from the research laboratory into the public domain, especially when it comes to technological advances that prevent and treat human disease. The Midwest Biomedical Accelerator Consortium (MBArC) will integrate academic and business development workflows to establish health-related small businesses that address high-burden diseases.
Researchers:

Human CD3epsilon co-potentiation to boost immunotherapy

Funding:
NIH National Cancer Institute, $3,730,200
Description:
This project takes a new approach to combat metastatic cancer using immunotherapy, with the goal of rapidly developing a clinical therapy to prolong the survival of patients suffering from metastatic melanoma and other cancers.
Researchers:

Efficacy of Metacognitive-Strategy Training to Improve Activity Performance and Reduce Motor Impairment in Sub-Acute Stroke

Funding:
National Institute of Child Health and Human Development, $2,769,495 (anticipated)
Description:
There is little evidence that current approaches to stroke rehabilitation help patients make meaningful improvements in the ability to perform everyday life activities. This project will evaluate a new metacognitive strategy that targets engagement in activity to identify better approaches to improving daily life for individuals with sub-acute stroke.
Researchers:

Role of S100 proteins in Diabetic Retinopathy

Funding
NIH National Eye Institute, $2,332,115 (anticipated)
Description
Diabetic retinopathy (DR) affects ~93 million diabetic people worldwide and often leads to blindness. Current treatments are expensive, only treat advanced stages of DR, require multiple injections and often failed to cure some patients. This project will lead to a better understanding of how DR works and help develop better DR treatments.
Researchers:
  • Shyam Sunder Chaurasia PI
  • Elizabeth A. Giuliano COI
  • Dean P. Hainsworth COI
  • Rajiv Ravindra Mohan COI

University of Missouri-Kansas City (UMKC)

Novel Prodrug Pharmacotherapy to Prevent Neuronal and Cell Degeneration in Age-related Macular Degeneration

Funding:
NIH National Eye Institute, $1,162,500 (anticipated)
Description:
Age-related Macular Degeneration (AMD) is a major cause of vision loss and blindness in the United States and worldwide. This project will evaluate new drugs for AMB to identify a therapy that is both preventative and therapeutic.
Researcher:

Missouri University of Science and Technology (S&T)

Novel Prodrug Pharmacotherapy to Prevent Neuronal and Cell Degeneration in Age-related Macular Degeneration

Funding:
National Science Foundation Office of Cyberinfrastructure, $1,960,000
Description:
Missouri currently lags far behind neighboring states in High-Performance Computing (HPC) capacity and coordination. This project is part of a new UM System strategic initiative to broaden HPC participation in Missouri, providing access, training and collaboration to many diverse groups who will not otherwise have these opportunities.
Researchers: